Pfizer Inc. News
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
see morePfizer Inc. Market News
4d
Pfizer's $0.43 Dividend & Matrix‑M Deal
- Pfizer reinforced shareholder returns with a $0.43 quarterly dividend while striking a strategic license with Novavax for the Matrix‑M adjuvant. These concrete moves — dividend continuity and a deal with explicit financial terms — materially affect PFE’s near‑term investor narrative and long‑term vaccine strategy.
17 Feb at 14:30
Pfizer Up: PF-3944 Data, BaseLaunch & Guidance Q2.
Pfizer’s recent week brought tangible catalysts: promising PF-3944 obesity data, a BaseLaunch partnership for early-stage access, confirmation of 2026 guidance and an FDA Priority Review for HYMPAVZI. These developments created near-term upside for PFE while setting a clear, pipeline-driven roadmap for 2026.